Synapse Open Synapse
Biology

With Setara, the team behind Actio opens its second act

BioPharma Dive · · 3 min read

The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.

Latest from BioPharma Dive